Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Diseases, Infectious

ClinicalTrials.gov lists 1,544 trials for Skin Diseases, Infectious or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 46.

MeSH D012874 Infections C01 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 159 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 326 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 277 Phase 4 Phase 4 131 Not applicable Not applicable 286 Observational Observational 281 Phase 1 Phase 1 159 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 326 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 277 Phase 4 Phase 4 131 Not applicable Not applicable 286 Observational Observational 281

Trials per phase

1 more section with rows

45 of the 1,544 trials are tagged with Skin Diseases, Infectious itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Diseases, Infectious report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Diseases, Infectious trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 103

1991: 3 trials (Observational 1, Phase 2/3 1, Phase 2 1) 1992: 4 trials (Phase 3 2, Phase 2 1, Phase 1 1) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Observational 1) 1995: 3 trials (Phase 2 1, Phase 1/2 2) 1996: 3 trials (Phase 3 2, Phase 2 1) 1997: 6 trials (Observational 1, Phase 3 5) 1998: 1 trials (Observational 1) 1999: 5 trials (Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1 1) 2000: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 2001: 7 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 1) 2002: 10 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2 1) 2003: 14 trials (Observational 1, Phase 4 2, Phase 3 7, Phase 2 3, Phase 1 1) 2004: 31 trials (Observational 1, Not applicable 5, Phase 4 4, Phase 3 7, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 2) 2005: 40 trials (Observational 5, Not applicable 4, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 3) 2006: 49 trials (Observational 9, Not applicable 4, Phase 4 9, Phase 3 12, Phase 2 11, Phase 1/2 1, Phase 1 3) 2007: 63 trials (Observational 2, Not applicable 12, Phase 4 4, Phase 3 14, Phase 2 20, Phase 1/2 1, Phase 1 10) 2008: 67 trials (Observational 12, Not applicable 10, Phase 4 7, Phase 3 12, Phase 2/3 5, Phase 2 17, Phase 1 4) 2009: 56 trials (Observational 9, Not applicable 13, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 14, Phase 1 5) 2010: 49 trials (Observational 4, Not applicable 8, Phase 4 6, Phase 3 13, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 2) 2011: 55 trials (Observational 7, Not applicable 6, Phase 4 6, Phase 3 18, Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 9) 2012: 64 trials (Observational 11, Not applicable 9, Phase 4 6, Phase 3 11, Phase 2/3 5, Phase 2 11, Phase 1/2 3, Phase 1 8) 2013: 48 trials (Observational 9, Not applicable 11, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 8, Phase 1/2 1, Phase 1 6) 2014: 49 trials (Observational 9, Not applicable 3, Phase 4 6, Phase 3 10, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 8) 2015: 66 trials (Observational 15, Not applicable 10, Phase 4 11, Phase 3 6, Phase 2/3 2, Phase 2 15, Phase 1 7) 2016: 65 trials (Observational 13, Not applicable 10, Phase 4 7, Phase 3 5, Phase 2 23, Phase 1/2 4, Phase 1 3) 2017: 68 trials (Observational 10, Not applicable 19, Phase 4 4, Phase 3 17, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 4) 2018: 67 trials (Observational 16, Not applicable 9, Phase 4 6, Phase 3 10, Phase 2/3 2, Phase 2 19, Phase 1/2 1, Phase 1 4) 2019: 68 trials (Observational 15, Not applicable 19, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 9) 2020: 76 trials (Observational 19, Not applicable 21, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 13, Phase 1 7) 2021: 75 trials (Observational 17, Not applicable 11, Phase 4 2, Phase 3 17, Phase 2 15, Phase 1/2 3, Phase 1 10) 2022: 84 trials (Observational 14, Not applicable 23, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 10, Phase 1/2 3, Phase 1 16) 2023: 71 trials (Observational 20, Not applicable 13, Phase 4 5, Phase 3 7, Phase 2/3 3, Phase 2 14, Phase 1/2 2, Phase 1 7) 2024: 64 trials (Observational 14, Not applicable 16, Phase 4 3, Phase 3 9, Phase 2/3 4, Phase 2 10, Phase 1 8) 2025: 103 trials (Observational 26, Not applicable 21, Phase 4 8, Phase 3 13, Phase 2/3 2, Phase 2 23, Phase 1/2 2, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 73
2025 103
2024 64
2023 71
2022 84
2021 75
2020 76
2019 68
2018 67
2017 68

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 91 trials starting in 2026 and about 89 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 28 months from start to primary completion across 102 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 1,031 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Diseases, Infectious trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 159
Phase 1/2 38
Phase 2 326
Phase 2/3 40
Phase 3 277
Phase 4 131
Not applicable 286
Observational 281
Expanded access 6

How many Skin Diseases, Infectious trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 65
Recruiting 136
Enrolling by invitation 3
Active, not recruiting 44
Available 3

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Diseases, Infectious trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 46
GlaxoSmithKline 34
Novartis Pharmaceuticals 30
Merck Sharp & Dohme LLC 24
Pfizer 23

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Skin Diseases, Infectious? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ivermectin 25
Itraconazole 23
Miltefosine 20
Meglumine Antimoniate 20
TERBINAFINE HYDROCHLORIDE (1%) 17

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Acyclovir 5% 27
Valacyclovir arrow 26
Vancomycin 1.1% 18
Adalimumab-US 16
Zyvox - linezolid 16

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Diseases, Infectious trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion induced 142 6
Abortion spontaneous 135 10
Hidradenitis 134 19
Cellulitis 122 47
Appendicitis 115 23

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Diseases, Infectious? (82)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Default Antibiotic Order Durations for Skin and Soft Tissue Infections in Outpatient Pediatrics: A Cluster Randomized Trial. Journal of the Pediatric Infectious Diseases Society 2025 Yes
Under the Skin: The Relationship Between Subcutaneous Injection and Skin Infections Among People Who Inject Drugs. Journal of addiction medicine 2022 Yes
Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial. Addiction (Abingdon, England) 2021 Yes
A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs. Drug and alcohol dependence 2021 Yes
Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2021 Yes

Showing 5 of 82 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages